Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management team will deliver a corporate presentation on Wednesday, February 12, 2025, at 12:00 PM Eastern Time.
The conference will be held virtually, and interested parties can access the presentation through a provided webcast link. Following the live presentation, a replay will be made available in the Events section of Cellectar's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB), un'azienda biofarmaceutica clinica in fase avanzata specializzata nello sviluppo di farmaci per il trattamento del cancro, ha annunciato la sua partecipazione alla prossima 35ª Conferenza Annuale sulla Salute e le Scienze della Vita di Oppenheimer. Il team di gestione dell'azienda presenterà una relazione aziendale mercoledì, 12 febbraio 2025, alle 12:00 PM (Ora Orientale).
La conferenza si svolgerà virtualmente e le parti interessate potranno accedere alla presentazione tramite un link web fornito. Dopo la presentazione in diretta, una registrazione sarà resa disponibile nella sezione Eventi del sito web delle relazioni con gli investitori di Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), una compañía biofarmacéutica clínica en etapa avanzada especializada en el desarrollo de medicamentos para el tratamiento del cáncer, ha anunciado su participación en la próxima 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. El equipo de gestión de la compañía llevará a cabo una presentación corporativa el miércoles, 12 de febrero de 2025, a las 12:00 PM (Hora del Este).
La conferencia se llevará a cabo de manera virtual, y las partes interesadas podrán acceder a la presentación a través de un enlace de transmisión web proporcionado. Tras la presentación en vivo, una grabación estará disponible en la sección de Eventos del sitio web de relaciones con inversionistas de Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), 암 치료 약물 개발에 전문화된 후기 단계 임상 생명공학 회사가 곧 있을 Oppenheimer 제35회 연례 건강 및 생명 과학 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 2025년 2월 12일 수요일, 동부 표준시 기준으로 오후 12시에 기업 발표를 진행할 예정입니다.
컨퍼런스는 온라인으로 개최되며, 관심 있는 분들은 제공된 웹 캐스트 링크를 통해 발표에 접근할 수 있습니다. 라이브 발표 후, Cellectar의 투자자 관계 웹사이트의 이벤트 섹션에서 리플레이가 제공될 예정입니다.
Cellectar Biosciences (NASDAQ: CLRB), une société biopharmaceutique clinique en phase avancée spécialisée dans le développement de médicaments pour le traitement du cancer, a annoncé sa participation à la prochaine 35e Conférence Annuelle Oppenheimer sur la Santé et les Sciences de la Vie. L'équipe de direction de la société donnera une présentation d'entreprise le mercredi 12 février 2025, à 12h00, heure de l'Est.
La conférence se déroulera virtuellement et les parties intéressées pourront accéder à la présentation via un lien de webdiffusion fourni. Après la présentation en direct, un replay sera disponible dans la section Événements du site Web des relations investisseurs de Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), ein biopharmazeutisches Unternehmen in einer späten klinischen Phase, das auf die Entwicklung von Krebsbehandlungsmedikamenten spezialisiert ist, hat seine Teilnahme an der bevorstehenden 35. jährlichen Oppenheimer Konferenz für Gesundheits- und Lebenswissenschaften angekündigt. Das Management-Team des Unternehmens wird am Mittwoch, den 12. Februar 2025, um 12:00 Uhr Eastern Time eine Unternehmenspräsentation halten.
Die Konferenz findet virtuell statt und interessierte Parteien können über einen bereitgestellten Webcast-Link auf die Präsentation zugreifen. Nach der Live-Präsentation wird eine Wiederholung im Bereich Veranstaltungen der Investor Relations-Website von Cellectar verfügbar sein.
- None.
- None.
FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually. Details are as follows:
Date: Wednesday, February 12, 2025
Time: 12:00 PM Eastern Time
Webcast: Click HERE
A replay of the corporate presentation will be available on the Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
FAQ
When is Cellectar Biosciences (CLRB) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch CLRB's presentation at the Oppenheimer Conference?
What is the format of CLRB's participation in the 2025 Oppenheimer Healthcare Conference?
What will be discussed in CLRB's presentation at the Oppenheimer Conference?
